colestilan inn trade name bindren medication acts phosphate bile acid ionexchange resin orally administered bile acid sequestrant developed mitsubishi tanabe pharma corporation treatment hypercholesterolaemia hyperphosphataemia launched japan hypercholesterolaemia treatment hyperphosphataemia launched austria germany czech republic portugal united kingdom registered eu phase iii development paediatric patients hyperphosphataemia associated chronic kidney disease underway uk germany however company discontinued development addition phase ii development diabetes mellitus phase development hyperphosphataemia japan also discontinued phase iii development hyperphosphataemia previously underway us however mitsubishi tanabe pharma discontinued development market colestilan also investigated phase iii trials europe asia hypercholesterolaemia however march recent reports development identified drug colestilan used treatment hyperphosphataemia high phosphate concentrations blood serum patients undergoing dialysis including peritoneal colestilan contraindicated patients bowel substance inhibit resorption drugs well fat soluble vitamins e k folate resulting lower blood levels clinically problematic immunosuppressant antiepileptic adverse effects include gastrointestinal problems constipation well vitamin calcium deficiency vitamin k deficiency sometimes causes gastrointestinal colestilan crosslinked copolymer epichlorohydrin works anion exchanger resin affinity phosphate bile acid anions urate binds anions gut removes enterohepatic circulation colestilan absorbed gut excreted together bound httpsenwikipediaorgwikicolestilan